Ryogena LLC Information

Drug discovery generates more signal than any team can manually interpret. The insight that advances your program already exists in your data — in the compound library, the assay history, the series you abandoned. Finding these insights is the problem AI solves. Understanding and accelerating success from these data is the problem Ryogena was built to solve. The name Ryogena comes from two Japanese kanji: 亮 (ryō — clarity, pictographically a high pavilion where light reaches) and 玄 (gen — profound depth, the character at the heart of the Japanese word for expert and the Zen concept of the temple gate, where passing through profound mystery is what leads to enlightenment). Clarity from the unseen. Ryogena builds AI-native software that helps research scientists make better decisions, faster. Our first product, Pico, is the AI copilot for the DMTA cycle in small molecule drug discovery — bolted onto your ELN, running alongside your chemistry, on your infrastructure. Your compound data never leaves your server. Built in regulated environments from line one of code. ALCOA+ audit trails. 21 CFR Part 11 ready. SOC 2 by release. Based in Cary, NC. Founded 2026.